Moving Beyond Serendipity to Mechanism-Driven Psychiatric Therapeutics.
Ontology highlight
ABSTRACT:
SUBMITTER: Pieper AA
PROVIDER: S-EPMC5509638 | biostudies-literature | 2017 Jul
REPOSITORIES: biostudies-literature
Publications
Moving Beyond Serendipity to Mechanism-Driven Psychiatric Therapeutics.
Pieper Andrew A AA Baraban Jay M JM
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20170701 3
Similar Datasets
Project description:The use of imaging systems in protein crystallisation means that the experimental setups no longer require manual inspection to determine the outcome of the trials. However, it leads to the problem of how best to find images which contain useful information about the crystallisation experiments. The adoption of a deeplearning approach in 2018 enabled a four-class machine classification system of the images to exceed human accuracy for the first time. Underpinning this was the creation of a labelled training set which came from a consortium of several different laboratories. The MARCO classification model does not have the same accuracy on local data as it does on images from the original test set; this can be somewhat mitigated by retraining the ML model and including local images. We have characterized the image data used in the original MARCO model, and performed extensive experiments to identify training settings most likely to enhance the local performance of a MARCO-dataset based ML classification model.
| S-EPMC10038243 | biostudies-literature
Project description:BackgroundHypertrophic cardiomyopathy (HCM) is a prevalent and complex cardiovascular condition. Despite being strongly associated with genetic alterations, wide variation of disease penetrance, expressivity and hallmarks of progression complicate treatment. We aimed to characterize different human isogenic cellular models of HCM bearing patient-relevant mutations to clarify genetic causation and disease mechanisms, hence facilitating the development of effective therapeutics.MethodsWe directly compared the p.β-MHC-R453C and p.ACTC1-E99K HCM-associated mutations in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and their healthy isogenic counterparts, generated using CRISPR/Cas9 genome editing technology. By harnessing several state-of-the-art HCM phenotyping techniques, these mutations were investigated to identify similarities and differences in disease progression and hypertrophic signaling pathways, towards establishing potential targets for pharmacological treatment. CRISPR/Cas9 knock-in of the genetically-encoded calcium indicator R-GECO1.0 to the AAVS1 locus into these disease models resulted in calcium reporter lines.ResultsConfocal line scan analysis identified calcium transient arrhythmias and intracellular calcium overload in both models. The use of optogenetics and 2D/3D contractility assays revealed opposing phenotypes in the two mutations. Gene expression analysis highlighted upregulation of CALM1, CASQ2 and CAMK2D, and downregulation of IRF8 in p.β-MHC-R453C mutants, whereas the opposite changes were detected in p.ACTC1-E99K mutants. Contrasting profiles of nuclear translocation of NFATc1 and MEF2 between the two HCM models suggest differential hypertrophic signaling pathway activation. Calcium transient abnormalities were rescued with combination of dantrolene and ranolazine, whilst mavacamten reduced the hyper-contractile phenotype of p.ACTC1-E99K hiPSC-CMs.ConclusionsOur data show that hypercontractility and molecular signaling within HCM are not uniform between different gene mutations, suggesting that a 'one-size fits all' treatment underestimates the complexity of the disease. Understanding where the similarities (arrhythmogenesis, bioenergetics) and differences (contractility, molecular profile) lie will allow development of therapeutics that are directed towards common mechanisms or tailored to each disease variant, hence providing effective patient-specific therapy.
| S-EPMC7487780 | biostudies-literature
Project description:Molecular "fingerprints" encoding structural information are the workhorse of cheminformatics and machine learning in drug discovery applications. However, fingerprint representations necessarily emphasize particular aspects of the molecular structure while ignoring others, rather than allowing the model to make data-driven decisions. We describe molecular graph convolutions, a machine learning architecture for learning from undirected graphs, specifically small molecules. Graph convolutions use a simple encoding of the molecular graph-atoms, bonds, distances, etc.-which allows the model to take greater advantage of information in the graph structure. Although graph convolutions do not outperform all fingerprint-based methods, they (along with other graph-based methods) represent a new paradigm in ligand-based virtual screening with exciting opportunities for future improvement.
| S-EPMC5028207 | biostudies-literature
Project description: Not available
| S-EPMC3219253 | biostudies-literature
Project description:Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by ineffective clonal hematopoiesis, splenomegaly, bone marrow fibrosis, and the propensity for transformation to acute myeloid leukemia. The discovery of mutations in JAK2, CALR, and MPL have uncovered activated JAK-STAT signaling as a primary driver of MF, supporting a rationale for JAK inhibition. However, JAK inhibition alone is insufficient for long-term remission and offers modest, if any, disease-modifying effects. Given this, there is great interest in identifying mechanisms that cooperate with JAK-STAT signaling to predict disease progression and rationally guide the development of novel therapies. This review outlines the latest discoveries in the biology of MF, discusses current clinical management of patients with MF, and summarizes the ongoing clinical trials that hope to change the landscape of MF treatment.
| S-EPMC6739355 | biostudies-literature
Project description:Livestock predation is a global problem and constitutes the main source of conflict between large carnivores and human interests. In Latin America, both jaguar and puma are known to prey on livestock, yet studies in Mesoamerica have been scattered and few have been carried out in Honduras. We interviewed ranchers in a biosphere reserve where jaguars and pumas are present. Local indigenous communities reported livestock predation (average annual loss of 7% from 2010-2019), with preventive and retaliatory killing as their main actions against predation by the jaguar and puma. Other sources of cattle loss included diseases and theft. The extensive management system (free grazing) lets cattle access forests where predators are more common. We found that livestock predation is not random, but rather, related to landscape variables and human influence. Sites farther from human influence and closer to forest cover were more susceptible to predation. Jaguar and puma persistence in the biosphere reserve will require measures that facilitate human-carnivore coexistence and comply with Sustainable Development Goals (SDG) 2 and 15 (zero hunger and biodiversity conservation). We propose management practices to mitigate livestock predation in the presence of large carnivores based on examples of proven human-carnivore coexistence in Venezuela, Brazil, Paraguay, and Nicaragua, such as improving the spatial arrangement of livestock (maintaining a distance from forest areas) and the incorporation of confinement pens for young calves (at least the first three months of life) and their mothers. If the pens are built close to the property's house and have constant surveillance and/or dogs, the results are likely to be more effective. Deploying these proven tools may help change the current negative perception of ranchers towards large carnivores that is essential to conservation under the aims of SDG 15. We recommend government policies and support aimed to strengthen livestock health to increase productivity and to reduce their vulnerability to predation. Finally, this study represents a baseline to understand the magnitude of the human-carnivore conflict over cattle in one of the largest biosphere reserves in Mesoamerica.
| S-EPMC8868381 | biostudies-literature
Project description: Not available
| S-EPMC8088594 | biostudies-literature
Project description: Not available
| S-EPMC7424244 | biostudies-literature
Project description:Identify DNA methylation change in retinoblastoma using aqueous humor cfDNA
2022-08-18 | GSE208053 | GEO
Project description:Microbial therapeutics, which include gut biotics and fecal transplantation, are interventions designed to improve the gut microbiome. Gut biotics can be considered as the administration of direct microbial populations. The delivery of this can be done through live microbial flora, certain food like fiber, microbial products (metabolites and elements) obtained through the fermentation of food products, or as genetically engineered substances, that may have therapeutic benefit on different health disorders. Dietary intervention and pharmacological supplements with gut biotics aim at correcting disruption of the gut microbiota by repopulating with beneficial microorganism leading to decrease in gut permeability, inflammation, and alteration in metabolic activities, through a variety of mechanisms of action. Our understanding of the pharmacokinetics of microbial therapeutics has improved with in vitro models, sampling techniques in the gut, and tools for the reliable identification of gut biotics. Evidence from human studies points out that prebiotics, probiotics and synbiotics have the potential for treating and preventing mental health disorders, whereas with paraprobiotics, proteobiotics and postbiotics, the research is limited at this point. Some animal studies point out that gut biotics can be used with conventional treatments for a synergistic effect on mental health disorders. If future research shows that there is a possibility of synergistic effect of psychotropic medications with gut biotics, then a gut biotic or nutritional prescription can be given along with psychotropics. Even though the overall safety of gut biotics seems to be good, caution is needed to watch for any known and unknown side effects as well as the need for risk benefit analysis with certain vulnerable populations. Future research is needed before wide spread use of natural and genetically engineered gut biotics. Regulatory framework for gut biotics needs to be optimized. Holistic understanding of gut dysbiosis, along with life style factors, by health care providers is necessary for the better management of these conditions. In conclusion, microbial therapeutics are a new psychotherapeutic approach which offer some hope in certain conditions like dementia and depression. Future of microbial therapeutics will be driven by well-done randomized controlled trials and longitudinal research, as well as by replication studies in human subjects.
| S-EPMC8510649 | biostudies-literature